SJZ No.4 Pharmaceutical SJZ No.4 Pharmaceutical

Corporate Email

中文/EN

简体中文

English

Tender Procurement

Public Tender Notice

Tender Information Release

Good News! On the same day, two products—Metoclopramide Hydrochloride Injection (2 mL: 10 mg) and Compound Electrolyte Sodium Acetate Glucose Injection (250 mL and 500 mL)—from Shijiazhuang Sihua Pharmaceutical Group were approved.

Category:

Honors Announcement

Time: 2026-04-10

【SUMMARY】 Innovation Brings Good News. On April 10, Shijiazhuang Sihua Pharmaceutical Group’s applications for Class 3 chemical drugs—metoclopramide hydrochloride injection (2 mL: 10 mg) and compound electrolyte sodium acetate-glucose injection (250 mL and 500 mL)—were approved by the National Medical Products Administration for manufacturing registration and are deemed to have passed the consistency evaluation. Since the beginning of this year, the Group has received approval for a total of 21 new products.
Good News! On the same day, two products—Metoclopramide Hydrochloride Injection (2 mL: 10 mg) and Compound Electrolyte Sodium Acetate Glucose Injection (250 mL and 500 mL)—from Shijiazhuang Sihua Pharmaceutical Group were approved.
Good News! On the same day, two products—Metoclopramide Hydrochloride Injection (2 mL: 10 mg) and Compound Electrolyte Sodium Acetate Glucose Injection (250 mL and 500 mL)—from Shijiazhuang Sihua Pharmaceutical Group were approved.

Innovation Brings Good News. On April 10, Shijiazhuang Sihua Pharmaceutical Group’s applications for Class 3 chemical drugs—metoclopramide hydrochloride injection (2 mL: 10 mg) and compound electrolyte sodium acetate-glucose injection (250 mL and 500 mL)—received production registration approval from the National Medical Products Administration, which also deems these products to have passed the consistency evaluation. Since the beginning of this year, the Group has secured approval for a total of 21 new products.

According to available information, Metoclopramide Hydrochloride Injection is an antiemetic indicated for vomiting induced by chemotherapy, radiotherapy, surgery, traumatic brain injury, post-traumatic sequelae, maritime and aviation operations, and drug administration; it is also used for the symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, uremia, and other conditions. Additionally, it is administered prior to diagnostic duodenal intubation to facilitate smooth insertion of the tube, and during gastrointestinal barium X-ray examinations to reduce nausea and vomiting and promote the passage of the barium contrast agent. Compound Electrolyte Sodium Acetate Glucose Injection is indicated for situations in which oral administration is not feasible or insufficient, to replenish and maintain fluid and electrolyte balance while providing energy.

In recent years, the Group has positioned itself in both domestic and international markets, continuously deepening its integrated, innovation-driven strategy that combines active pharmaceutical ingredients (APIs) with finished dosage forms, and vigorously advancing the high-end development of injectables, the diversification of oral formulations, and the specialized development of APIs.

In February 2026, the metoclopramide hydrochloride API developed by Guangxiang Pharmaceutical of the Group successfully changed its registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as an API used in marketed dosage forms. Just over a month later, the approval of metoclopramide hydrochloride injection fully demonstrated the company’s strength and advantages in integrated innovation spanning both APIs and finished dosage forms, laying a solid foundation for subsequent industrial-chain extension and synergistic development of product clusters.

Focusing on the nutritional supplement segment of the pharmaceutical market, the Group continues to refine its product portfolio for electrolyte and acid–base balance, as well as mineral and general nutritional supplements. To date, the Group offers a range of clinical nutrition supplements, including Compound Sodium Acetate Electrolyte Injection (500 mL), Compound Electrolyte Injection (V) (500 mL), Compound Sodium Acetate Ringer’s Injection (500 mL), Sodium Acetate Ringer’s Injection, Sodium Acetate Ringer’s Glucose Injection, Fat-Soluble Vitamin Injection (II), and Sodium Glycero-Phosphate Injection (10 mL: 2.16 g). The recent approval and launch of two new specifications—Compound Sodium Acetate Glucose Injection (250 mL and 500 mL)—will provide clinicians with more diversified therapeutic options.

To date, the Group has had a total of 175 drug varieties and 229 dosage forms either approved or deemed to have passed the evaluation of generic drug quality and therapeutic equivalence. In addition, the Group boasts 99 bulk specialty active pharmaceutical ingredients, thereby continuously injecting new momentum into the company’s innovative, high-quality development through a robust product portfolio.

Keywords:

Previous

None

Shijiazhuang Sihua Pharmaceutical Group’s Tranexamic Acid Tablets (0.25 g) Have Been Approved

Next

Previous:

None

Next:

Shijiazhuang Sihua Pharmaceutical Group’s Tranexamic Acid Tablets (0.25 g) Have Been Approved